Anti-IQGAP1 antibody

• IHC-P

AbReview28933****

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IQGAP1 antibody (AB86064)

ab86064 staining IQGAP1 in human pacreatic islets by Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections).

Tissue was fixed in paraformaldehyde and a heat mediated antigen retrieval step was performed using citrate. Samples were then blocked with 5% serum for 1 hour at 20°C and then incubated with ab86064 at a 1/100 dilution for 8 hours at 4°C. The secondary used was a biotin conjugated goat anti-rabbit polyclonal used at a 1/1000 dilution.

Image courtesy of an anonymous Abreview.

• IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IQGAP1 antibody (AB86064)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human breast carcinoma tissue labelling IQGAP1 with ab86064 at 1/1000 (0.2µg/ml) and 1/200 (1µg/ml). Detection : DAB and a DyLight® 594-conjugated goat anti-rabbit IgG (H+L) (1/100).

• IP

Unknown

Immunoprecipitation - Anti-IQGAP1 antibody (AB86064)

Detection of IQGAP1 by Western Blot of Immunprecipitate.
ab86064 at 0.4µg/ml staining IQGAP1 in HeLa whole cell lysate immunoprecipitated using ab86064 at 3µg/mg lysate (1 mg/IP; 20% of IP loaded/lane).
Detection : Chemiluminescence with exposure time of 10 seconds.

All lanes:

Immunoprecipitation - Anti-IQGAP1 antibody (ab86064)

Predicted band size: 189 kDa

false

• WB

Unknown

Western blot - Anti-IQGAP1 antibody (AB86064)

All lanes:

Western blot - Anti-IQGAP1 antibody (ab86064) at 0.04 µg/mL

Lane 1:

HeLa whole cell lysate at 50 µg

Lane 2:

HeLa whole cell lysate at 15 µg

Lane 3:

HeLa whole cell lysate at 5 µg

Lane 4:

293T whole cell lysate at 50 µg

Predicted band size: 189 kDa

Observed band size: 189 kDa,238 kDa

false

Exposure time: 10s

• WB

CiteAb

Western blot - Anti-IQGAP1 antibody (AB86064)

IQGAP1 western blot using anti-IQGAP1 antibody ab86064. Publication image and figure legend from Zheng, X., Hu, X., et al., 2019, Int J Med Sci, PubMed 31523178.

ab86064 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab86064 please see the product overview.

Imatinib attenuated vascular smooth muscle cell phenotype switching to a migration state by IQGAP1. (A), The changes of α-SMA and SM22 expression were mediated by imatinib. Quantification of α-SMA is shown in A1; ** : P<0.01, CULSMC Control vs CULSMC LPS, ## : P<0.01, CULSMC LPS vs SMCs were treated with LPS and imatinib in co-culture system (CULSMC LPS + imatinib). Quantification of SM22 expression is shown in A2; * : P<0.05, CULSMC Control vs CULSMC LPS, # : P<0.05, CULSMC LPS vs CULSMC LPS + imatinib; (B) LPS induced an increase in the migration ability of SMCs in the co-culture system were attenuated by imatinib. Quantification of B is shown in B1, ** : P<0.01, CULSMC Control vs CULSMC LPS, ## : P<0.01, CULSMC LPS vs CULSMC LPS + imatinib; (C) The change of IQGAP1 expression was mediated by imatinib. Quantification of IQGAP1 is shown in C1; ** : P<0.01, CULSMC Control vs CULSMC LPS, ## : P<0.01, CULSMC LPS vs CULSMC LPS + imatinib.

false